Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUNDRA-AF dose-escalation study of intravenous K201 for recent-onset atrial fibrillation
2010-023101-35Phase 2Terminated
- Sponsor
- Sequel Pharmaceuticals
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of K201 in Atrial fibrillation (AFib) (4 arms), sponsored by Sequel Pharmaceuticals. Primary endpoints: Conversion to sinus rhythm, Change in atrial fibrillation symptom score and 2 more. Started Jan 2011; status: terminated.
02
Drugs
K201
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2010-023101-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023101-35.